^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)

    i
    Other names: CDKN2B, Cyclin Dependent Kinase Inhibitor 2B, Cyclin-Dependent Kinase Inhibitor 2B (P15, Inhibits CDK4), Cyclin-Dependent Kinase 4 Inhibitor B, Multiple Tumor Suppressor, P14-INK4b, P15-INK4b, MTS-2, MTS2, Cyclin-Dependent Kinases 4 And 6 Binding Protein, CDK Inhibitory Protein, P14_CDK Inhibitor, P15 CDK Inhibitor, CDK4B Inhibitor, P14_INK4B, P15_INK4B, P15INK4b, P15INK4B, CDK4I, INK4B, TP15, P15
    3d
    ALK Inhibitor Response in Novel ZFPM2::ALK and TRIM24::ALK Fusion-Positive Lung Cancers: Case Report. (PubMed, JTO Clin Res Rep)
    The patient with TRIM24::ALK fusion, following durable responses to alectinib and lorlatinib, relapsed with detection of on-target ALK kinase domain mutations (F1174V, I1171N) and MYC amplification on progression. Comprehensive molecular workup, including RNA-based NGS, is essential for detecting rare but actionable ALK rearrangements and optimizing therapeutic strategy. NGS of CSF was a valuable tool for the detection of clinically suspected leptomeningeal disease and disease monitoring.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • EML4 (EMAP Like 4) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • TRIM24 (Tripartite Motif Containing 24)
    |
    ALK positive • ALK rearrangement • ALK fusion • CDKN2A deletion
    |
    Alecensa (alectinib) • Lorbrena (lorlatinib)
    3d
    A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy (clinicaltrials.gov)
    P2, N=45, Active, not recruiting, Eli Lilly and Company | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
    |
    CDKN2A deletion • IDH wild-type
    |
    temozolomide • Verzenio (abemaciclib)
    5d
    Malignant transformation of fibrous dysplasia in long bones: a clinicopathological and molecular study of 19 cases. (PubMed, J Clin Pathol)
    Our analysis revealed unique clinicopathological characteristics and genetic markers in FD-associated sarcomas, deepening our knowledge of the mechanisms behind malignant transformation in FD and offering diagnostic tools for enhanced pathological assessment.
    Journal
    |
    TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • KDM6A (Lysine Demethylase 6A) • GNAS (GNAS Complex Locus)
    6d
    Toripalimab in Patients with Previously Treated Advanced Upper Tract Urothelial Carcinoma: A Subgroup Analysis of the Phase II POLARIS-03 Trial. (PubMed, Oncologist)
    Toripalimab demonstrated promising activity and manageable safety in pretreated mUTUC. High TMB was associated with numerically improved outcomes, suggesting its potential role as an exploratory biomarker for response to PD-1 blockade in this population.
    P2 data • Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • FGFR3 (Fibroblast growth factor receptor 3) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TERT (Telomerase Reverse Transcriptase) • KMT2D (Lysine Methyltransferase 2D) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    PD-L1 expression • TP53 mutation • TMB-H
    |
    Loqtorzi (toripalimab-tpzi)
    9d
    Molecular and clinical prognostic factors in isocitrate dehydrogenase-mutant astrocytomas: Insights into biomarker-driven stratification. (PubMed, J Neuropathol Exp Neurol)
    Our study validates the prognostic value of the WHO 2021 classification for IDH-mutant astrocytomas and demonstrates that MET and PDGFRA alterations are independent adverse prognostic factors, comparable to CDKN2A/B HD. Their cumulative burden enables refined molecular risk stratification to guide clinical management.
    Clinical • Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
    |
    CDKN2A deletion • MET mutation
    9d
    Pediatric NTRK-rearranged gliomas: A clinicopathological and molecular analysis of six cases. (PubMed, Pathol Res Pract)
    This study expands the clinicopathological and molecular spectrum of pediatric NTRK-rearranged gliomas, including rare entities and complex fusion patterns, and supports routine NTRK testing in pediatric gliomas irrespective of histological grade.
    Journal
    |
    TP53 (Tumor protein P53) • ABL1 (ABL proto-oncogene 1) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ETV6 (ETS Variant Transcription Factor 6) • MSH2 (MutS Homolog 2) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • CHEK1 (Checkpoint kinase 1) • NTRK (Neurotrophic receptor tyrosine kinase) • ARHGEF11 (Rho Guanine Nucleotide Exchange Factor 11)
    |
    NTRK fusion
    10d
    Giant cutaneous melanoma presenting with hemorrhagic complications. (PubMed, Acta Dermatovenerol Alp Pannonica Adriat)
    This case underscores the urgent need for timely recognition and intervention in giant melanoma with acute complications. It also highlights the effectiveness of modern adjuvant therapies in improving prognosis.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PTEN (Phosphatase and tensin homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • ARID2 (AT-Rich Interaction Domain 2)
    |
    BRAF V600 • PTEN mutation
    11d
    Anaplastic ovarian mucinous carcinoma with yolk sac differentiation: a rare case report and literature review. (PubMed, AME Case Rep)
    Gene mutations were identified in some of the cases, for instance CDKN2A and CDKN2B genes deletion, as well as KRAS and TP53 genes mutation. This tumor is highly aggressive, 75.0% (6/8) of the cases recurred or dead within one year of diagnosis.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
    |
    TP53 mutation • KRAS mutation • CDKN2A deletion
    12d
    The prognostic impact of CDKN2A/B hemizygous deletions in meningioma. (PubMed, Neuro Oncol)
    Our findings suggest that hemizygous CDKN2A/B deletions overall do not confer worse risks for progression in meningiomas. The signal for segmental deletions may not be locus-specific but just one representation of the generally instable genome of aggressive meningiomas.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
    |
    CDKN2A deletion
    13d
    Concurrent Retinoblastoma 1 (RB1) and IKZF1 Deletions Have Adverse Outcome in Childhood B-Cell Acute Lymphoblastic Leukemia (B-ALL). (PubMed, Int J Lab Hematol)
    The B-ALL patients with concurrent RB1 and IKZF1 deletions had worse outcomes compared to cases without any of these deletions. The RB1 deletion increased the risk of early events in patients with the IKZF1plus profile.
    Journal • Adverse events
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • IKZF1 (IKAROS Family Zinc Finger 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • PAX5 (Paired Box 5)
    |
    CDKN2A deletion • RB1 deletion
    13d
    Pembrolizumab, Olaparib, and Temozolomide for People With Glioma (clinicaltrials.gov)
    P2, N=57, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • FGFR (Fibroblast Growth Factor Receptor) • CDK12 (Cyclin dependent kinase 12) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • CHEK2 (Checkpoint kinase 2) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • BARD1 (BRCA1 Associated RING Domain 1) • RAD54L (DNA Repair And Recombination Protein RAD54) • FANCL (FA Complementation Group L) • PPP2R2A (Protein Phosphatase 2, Regulatory Subunit B, Alpha)
    |
    CDKN2A deletion • BRIP1 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • IDH wild-type
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • temozolomide
    17d
    A Case of Malignant Melanoma With Numerous Wagner-Meissner-Like Bodies. (PubMed, Am J Dermatopathol)
    Chromosomal microarray identified heterozygous loss of 9p22.1p13.1 (including CDKN2A/CDKN2B), and loss of 10q22.2q26.3 (including PTEN), supporting malignancy. These findings suggest that in this case, Wagner-Meissner-like bodies likely represent neurotization rather than a benign or collision lesion, highlighting the need for integrated histopathologic, immunohistochemical, and molecular analysis in challenging melanocytic neoplasms.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • PRAME (Preferentially Expressed Antigen In Melanoma)